Friday, January 20, 2012

Cooperative Dual-Activity Targeted Nanomedicine for Specific and Effective Prostate Cancer Therapy

Supra-magnetic nanoparticles combined with anti-PSMA antibodies and carrying paclitaxel result in a 20-fold increase in drug concentration at the target site - if this can be replicated in human subjects it would be a huge move forward for patients with prostate cancer - and perhaps even other cancers given that PSMA is expressed in most tumor neovasculature -- higher drug concentrations at the target tissue mean less side effects on non-target tissues -- read all about it here